Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

Ciclosporin A proof of concept study in patients with active, progressive HTLV-1 associated myelopathy/tropical spastic paraparesis.

Martin F, Castro H, Gabriel C, Adonis A, Fedina A, Harrison L, Brodnicki L, Demontis MA, Babiker AG, Weber JN, Bangham CR, Taylor GP.

PLoS Negl Trop Dis. 2012;6(6):e1675. doi: 10.1371/journal.pntd.0001675. Epub 2012 Jun 12.

2.

Tropical spastic paraparesis and HTLV-1 associated myelopathy: clinical, epidemiological, virological and therapeutic aspects.

Gessain A, Mahieux R.

Rev Neurol (Paris). 2012 Mar;168(3):257-69. doi: 10.1016/j.neurol.2011.12.006. Epub 2012 Mar 7. Review.

PMID:
22405461
3.

Cyclosporine for the treatment of HLTV-1-induced HAM/TSP: an experience from a case report.

Sánchez-Montalvá A, Salvador F, Caballero E, Molina I.

Medicine (Baltimore). 2015 Jan;94(1):e382. doi: 10.1097/MD.0000000000000382. Erratum in: Medicine (Baltimore). 2015 Feb;94(6):1.

4.

Therapeutic strategies in HTLV-I-associated myelopathy/tropical spastic paraparesis (HAM/TSP).

Nakamura T, Nishiura Y, Eguchi K.

Cent Nerv Syst Agents Med Chem. 2009 Jun;9(2):137-49. Review.

PMID:
20021347
5.
6.

Incidence of human T cell lymphotropic virus type 1-associated myelopathy/tropical spastic paraparesis in a long-term prospective cohort study of initially asymptomatic individuals in Brazil.

Romanelli LC, Caramelli P, Martins ML, Gonçalves DU, Proietti FA, Ribas JG, Araújo MG, Carneiro-Proietti AB.

AIDS Res Hum Retroviruses. 2013 Sep;29(9):1199-202. doi: 10.1089/AID.2013.0086. Epub 2013 May 31.

PMID:
23617363
7.

Therapeutic trials in 200 patients with HTLV-I-associated myelopathy/ tropical spastic paraparesis.

Nakagawa M, Nakahara K, Maruyama Y, Kawabata M, Higuchi I, Kubota H, Izumo S, Arimura K, Osame M.

J Neurovirol. 1996 Oct;2(5):345-55.

PMID:
8912211
8.

Presence of tropical spastic paraparesis/human T-cell lymphotropic virus type 1-associated myelopathy (TSP/HAM)-like among HIV-1-infected patients.

Casseb J, de Oliveira AC, Vergara MP, Montanheiro P, Bonasser F, Meilman Ferreira C, Smid J, Duarte AJ.

J Med Virol. 2008 Mar;80(3):392-8. doi: 10.1002/jmv.21111.

PMID:
18205234
9.

Increased expression of OX40 is associated with progressive disease in patients with HTLV-1-associated myelopathy/tropical spastic paraparesis.

Saito M, Tanaka R, Arishima S, Matsuzaki T, Ishihara S, Tokashiki T, Ohya Y, Takashima H, Umehara F, Izumo S, Tanaka Y.

Retrovirology. 2013 May 7;10:51. doi: 10.1186/1742-4690-10-51.

10.

[The current and future approaches to the treatment of HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP)].

Yamano Y, Sato T, Ando H, Araya N, Yagishita N.

Nihon Rinsho. 2012 Apr;70(4):705-13. Japanese.

PMID:
22568157
11.

Molecular and clinical effects of betamethasone in human T-cell lymphotropic virus type-I-associated myelopathy/tropical spastic paraparesis patients.

Alberti C, Cartier L, Valenzuela MA, Puente J, Tanaka Y, Ramirez E.

J Med Virol. 2011 Sep;83(9):1641-9. doi: 10.1002/jmv.22131.

PMID:
21739457
12.

Falls in patients with HTLV-I-associated myelopathy/tropical spastic paraparesis (HAM/TSP).

Facchinetti LD, Araújo AQ, Chequer GL, de Azevedo MF, de Oliveira RV, Lima MA.

Spinal Cord. 2013 Mar;51(3):222-5. doi: 10.1038/sc.2012.134. Epub 2012 Nov 20.

PMID:
23165507
13.

[Tropical spastic paraparesis in a non tropical region].

Pias-Peleteiro L, Pias-Peleteiro JM, Arias M.

Rev Neurol. 2015 Oct 16;61(8):357-62. Spanish.

14.

Risk factors and cofactors for human T-cell lymphotropic virus type I (HTLV-I)-associated myelopathy/tropical spastic paraparesis (HAM/TSP) in Jamaica.

Krämer A, Maloney EM, Morgan OS, Rodgers-Johnson P, Manns A, Murphy EL, Larsen S, Cranston B, Murphy J, Benichou J, et al.

Am J Epidemiol. 1995 Dec 1;142(11):1212-20.

PMID:
7485068
15.

CD80+ and CD86+ B cells as biomarkers and possible therapeutic targets in HTLV-1 associated myelopathy/tropical spastic paraparesis and multiple sclerosis.

Menezes SM, Decanine D, Brassat D, Khouri R, Schnitman SV, Kruschewsky R, López G, Alvarez C, Talledo M, Gotuzzo E, Vandamme AM, Galvão-Castro B, Liblau R, Weyenbergh JV.

J Neuroinflammation. 2014 Jan 29;11:18. doi: 10.1186/1742-2094-11-18.

16.

Long-term, high dose interferon-alpha treatment in HTLV-I-associated myelopathy/tropical spastic paraparesis: a combined clinical, virological and immunological study.

Yamasaki K, Kira J, Koyanagi Y, Kawano Y, Miyano-Kurosaki N, Nakamura M, Baba E, Suzuki J, Yamamoto A, Yamamoto N, Kobayashi T.

J Neurol Sci. 1997 Apr 15;147(2):135-44.

PMID:
9106118
17.
18.

Minocycline modulates antigen-specific CTL activity through inactivation of mononuclear phagocytes in patients with HTLV-I associated neurologic disease.

Enose-Akahata Y, Matsuura E, Tanaka Y, Oh U, Jacobson S.

Retrovirology. 2012 Feb 15;9:16. doi: 10.1186/1742-4690-9-16.

19.

Intravenous methylprednisolone in HTLV-I associated myelopathy/tropical spastic paraparesis (HAM/TSP).

Araújo AQ, Afonso CR, Leite AC, Dultra SV.

Arq Neuropsiquiatr. 1993 Sep;51(3):325-8.

PMID:
8297234
20.

In vivo expression of the HBZ gene of HTLV-1 correlates with proviral load, inflammatory markers and disease severity in HTLV-1 associated myelopathy/tropical spastic paraparesis (HAM/TSP).

Saito M, Matsuzaki T, Satou Y, Yasunaga J, Saito K, Arimura K, Matsuoka M, Ohara Y.

Retrovirology. 2009 Feb 19;6:19. doi: 10.1186/1742-4690-6-19.

Supplemental Content

Support Center